Navigation Links
Herceptin + Hormonal Therapy Pack Reduces Breast Cancer Progression

In a new study, Roche Holding AG (RHHBY), a Swiss pharmaceutical company says, breast cancer progression decreases when Herceptin was added to hormonal therapy//. When the patient condition is hormone receptor-positive, as well as HER2-positive, this combined therapy proves to be progression-free. Hormone receptor-positive breast cancer results lower risk rate whereas HER2-positive breast cancer aggressive form of the disease that requires special and immediate attention due to fast- developing tumour.

Eduard Holdener, Global Head of Roche Pharma Development reported that a combination therapy proved a new better treatment for breast cancer patients, who suffer from an extremely aggressive form of the disease. AII over the world nearly above 230,000 patients with HER2-positive breast cancer are trailed for treatment with Herceptin. And whether used alone or with other combination of therapies Herceptin consistently benefits patients.

Across the world, in 25 countries about 208 HER2 and hormone receptor co-positive patients were enrolled at 134 sites.The randomised, Phase III trial, conducted by Roche started in 2001 which evaluated Herceptin plus Arimidex versus Armidex alone as first-line therapy -or second line hormonal therapy- in postmenopausal women with advanced, HER2-positive and hormone receptor-positive breast cancer -TAnDEM study reports.

Arimidex - a dose of 1 mg daily and Herceptin a dose of 2 mg/kg weekly were given after an initial loading dose of 4 mg/kg, until disease progression. At the end, patients who received Herceptin had a statistically significant improvement in progression-free survival.

Overall safety data and side-effects were continued to be followed.


'"/>




Page: 1

Related medicine news :

1. Nurse wins her case over use of Herceptin for her Breast cancer
2. Drug Herceptin To Be Recommended To All Breast Cancer Patients
3. Herceptin Is A Possible Cure For Breast Cancer
4. Herceptin Not A ‘Wonder’ Drug, Says The Lanct
5. ￡6000 to be refunded to Mrs. Leese for Herceptin treatmen
6. Wangaratta Community fundraising for Herceptin drug
7. Herceptin for Early Stage Breast cancer
8. Treatment of Breast Cancer with Herceptin for Nine Weeks
9. Herceptin is the cure for early stages of breast cancer?
10. 10-year-old Pleads, Herceptin For My Mum, Please
11. Norfolk PCTs To Offer Herceptin
Post Your Comments:
(Date:7/25/2008)... Though the number of jobs created...al companies reported a different kind of slowdown...ous months. , Seattle, WA...s created in the medical field slowed in June over... kind of slowdown that will be music to the ears o...
(Date:7/25/2008)...cKesson Corporation Executive, Robert J. Reilly, J.../ -- Aethon Inc.,( http://www.aethon.com ), the le...pply chain logistics, today announced that Robert ...esident -- Chief Financial Officer., Reilly, who ...r for,McKesson Corporation,s Specialty Pharmacy Di...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Drug Information Association ...ill host the Critical Path Initiative (CPI) on the...16; Bethesda, MD) and the Critical Path Transporte... Horsham, PA (PRWEB) July 25...mation Association (DIA)] and the Food and Drug Ad...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3
...gy segment, pharma major Dr Reddys Laboratories Lt...ailable// in extended release tablets of 10 mg dos...he brand name 'Alfoo' is indicated for treatment o...ing men known as Benign Prostatic Hyperplasia (BPH...
...overed a method to cease the blood supply to cance... cancer//. This, if proved conclusively, will infu...ng to the scientists, a protein, discovered while ...pable of stopping the blood supply to tumors, thus...
...tropolis Health Services (India) plans to make Dub...dle East//. In a joint venture with United Arab Em... Metropolis is set to begin formal operations of i...i in August, though the soft launch took place las...
...ter when investigating for an alternative menopaus...ated hot flashes as good as estrogen. Gabapentin,...the flow of calcium in and out of the cells, which...ature. flow risks like was researchers, who have ...
Other Medicine News:Health News:Metropolis Health Plans Middle East hub in Dubai 2Health News:Gabapentin Reduced Menopausal Symptoms as Estrogen – Study Find 2
(Date:7/24/2008)...EW, Calif., July 24 /- Alex...d today that it has initiated,its second Phase 3 c...AZ-004 is an inhalation product candidate being de...tients with schizophrenia or bipolar disorder.,Ale...pid pharmacokinetic,(PK) properties resulting from...
(Date:7/24/2008)...uly 24 /- MacroChem Corpora...sults of a Phase 2 clinical trial,involving 37 pat...open-label efficacy and safety study of EcoNail, a...nychomycosis (nail fungus). The composite,primary ... defined as,negative mycology (negative fungal cul...
(Date:7/23/2008)... July 23 /PRNewswire-USNewswire/ -- The following ...Chairman Conyers, Ranking Member Smith, and Member...to testify today., Since I appeared before this C... better acquainted with the talented and dedicated...the work they do, and I have come to,appreciate th...
(Date:7/23/2008)...used on IND-Enabling Work with Protein Therapeutic...omplement System, CAMBRIDGE, Mass., July 23 /PRNe...ed it has initiated a corporate growth plan with t...executive officer and the,establishment of its hea...s,Woodruff Emlen, M.D., a co-founder of the compan...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Brown named Center of Excellence in Geriatric Medicine and Training 8968 1Brown named Center of Excellence in Geriatric Medicine and Training 8968 2Brown named Center of Excellence in Geriatric Medicine and Training 8968 3American College of Physicians receives grant to study cost of patient centered medical home 8965 1American College of Physicians receives grant to study cost of patient centered medical home 8965 2New discovery could reduce the health risk of high fat foods 1754 1Resilience concepts poised to aid management of coastal marine ecosystems 1751 1Resilience concepts poised to aid management of coastal marine ecosystems 1751 2
...Newswire-FirstCall/ -- Rigel Pharmaceuticals, Inc....s currently in ongoing,Phase 2 clinical trials in ...arthritis (RA) and lymphoma patients. R788 is a no...ivation of mast cells,macrophages and B-cells tha...sue damage. , Rigel commenced an exploratory Phase...
...ce in Barcelona,Spain, VANCOUVER and SAN DIEGO, C... Inc. , a clinical-stage developer,of drugs for in...ts,confirming the previously announced clinical re...inical benefit, safety and,tolerability in a Phase...or, celgosivir (MX-3253), in combination with pegy...
Other Medicine Technology:Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 2Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 3Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8